The safety of vaccines

Drug Discovery Today

Volumn 9, Issue 19, 2004, Pages 846-854

  O'Hagan, Derek T ^a   Rappuoli, Rino ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b CHIRON VACCINES   (Italy)

Author keywords

Drug Discovery; Immunization policy; Infectious disease; Pediatric vaccines; Pharmaceutical Science; Therapeutic vaccines; Vaccine adjuvants; Vaccine controversies; Virology

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS B VACCINE; HYDROXIDE; INACTIVATED VIRUS VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; ORAL POLIOMYELITIS VACCINE; PENICILLIN G; PERTUSSIS VACCINE; PHOSPHATE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE VACCINE; ROTAVIRUS VACCINE; THIOMERSAL; VACCINE; VANCOMYCIN;

ALLERGY; ANAPHYLAXIS; ASTHMA; AUTISM; AUTOIMMUNE DISEASE; DIABETES MELLITUS; DRUG CONJUGATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ERYTHEMA; FEVER; GENE MUTATION; HEALTH CARE POLICY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INFANTILE SPASM; INFECTION; INTERPERSONAL COMMUNICATION; INTUSSUSCEPTION; MACROPHAGIC MYOFASCITIS; MALAISE; MULTIPLE SCLEROSIS; MUSCLE HYPOTONIA; MYOSITIS; NEUROLOGIC DISEASE; PAIN; PARALYTIC POLIOMYELITIS; PEANUT; PERTUSSIS; POLIOMYELITIS; PRACTICE GUIDELINE; REVIEW; SEIZURE; STAPHYLOCOCCUS INFECTION; VIRULENCE; VIRUS INFECTION;

ANAPHYLAXIS; AUTOIMMUNE DISEASES; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; IMMUNIZATION; UNITED STATES; VACCINES;

EID: 4644245384     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03234-9     Document Type: Review

References (56)

1. Ehreth J. The value of vaccination: a global perspective. Vaccine. 21:2003;4105-4117
2. Jodar L., et al. Ensuring vaccine safety in immunization programmes - a WHO perspective. Vaccine. 19:2001;1594-1605
3. Confavreux C., et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in multiple sclerosis study group. N. Engl. J. Med. 344:2001;319-326
4. Ascherio A., et al. Hepatitis B vaccination and the risk of multiple sclerosis. N. Engl. J. Med. 344:2001;327-332
5. O'Hagan D., Rappuoli R. Novel approaches to vaccine delivery. Pharm. Res. 21:2004;1519-1530
6. Duclos P. A global perspective on vaccine safety. Vaccine. 22:2004;2059-2063
7. Clements C.J., et al. Technologies that make administration of vaccines safer. Vaccine. 22:2004;2054-2058
8. Demicheli V., Jefferson T. The first international symposium on vaccine safety. Vaccine. 22:2004;2042-2043
9. Murphy T.V., et al. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 344:2001;564-572
10. Chang H.G., et al. Intussusception, rotavirus diarrhea, and rotavirus vaccine use among children in New York state. Pediatrics. 108:2001;54-60
11. Murphy B.R., et al. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J. Infect. Dis. 187:2003;1301-1308
12. Strebel P.M., et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin. Infect. Dis. 14:1992;568-579
13. Strickler H.D., et al. Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. J. Am. Med. Assoc. 279:1998;292-295
14. Strom J. Further experience of reactions, especially of a cerebral nature, in conjunction with triple vaccination: a study based on vaccinations in Sweden 1959-65. Br. Med. J. 4:1967;320-323
15. Stewart G.T. Toxicity of pertussis vaccine. Lancet. 2:1977;1130
16. Gangarosa E.J., et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet. 351:1998;356-361
17. Miller D., et al. Pertussis immunization and serious acute neurological illnesses in children. Br. Med. J. 307:1993;1171-1176
18. Rappuoli R. Acellular pertussis vaccines: a turning point in infant and adolescent vaccination. Infect. Agents Dis. 5:1996;21-28
19. Hviid A., et al. Childhood vaccination and type 1 diabetes. N. Engl. J. Med. 350:2004;1398-1404
20. DeStefano F., et al. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. Pediatrics. 108:2001;E112
21. Rutschmann O.T., et al. Immunization and MS: a summary of published evidence and recommendations. Neurology. 59:2002;1837-1843
22. Wraith D.C., et al. Vaccination and autoimmune disease: what is the evidence? Lancet. 362:2003;1659-1666
23. Bohlke K., et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 112:2003;815-820
24. Offit P.A., Jew R.K. Addressing parents' concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics. 112:2003;1394-1397
25. Pichichero M.E., et al. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet. 360:2002;1737-1741
26. Singh M., O'Hagan D.T. Recent advances in vaccine adjuvants. Pharm. Res. 19:2002;715-728
27. Clements C.J., Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine. 20:(Suppl. 3):2002;S24-S33
28. Keith L.S., et al. Aluminum toxicokinetics regarding infant diet and vaccinations. Vaccine. 20 (Suppl. 3):2002;S13-S17
29. Jefferson T., et al. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect. Dis. 4:2004;84-90
30. Gherardi R.K., et al. Macrophagic myofascitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Francaise contre les Myopathies (AFM). Lancet. 352:1998;347-352
31. McKeever T.M., et al. Vaccination and allergic disease: a birth cohort study. Am. J. Public Health. 94:2004;985-989
32. Wakefield A.J., et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 351:1998;637-641
33. Murch S.H., et al. Retraction of an interpretation. Lancet. 363:2004;750
34. Gregson A.L., Edelman R. Does antigenic overload exist? The role of multiple immunizations in infants. Immunol. Allergy Clin. North Am. 23:2003;649-664
35. Offit P.A., et al. Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics. 109:2002;124-129
36. Townley R.G., et al. The effect of BCG vaccine at birth on the development of atopy or allergic disease in young children. Ann. Allergy Asthma Immunlo. 92:2004;350-355
37. Ota M.O., et al. Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J. Immunol. 168:2002;919-925
38. Balmer P., et al. Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol. 51:2002;717-722
39. Klugman K.P. Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. Lancet Infect. Dis. 1:2001;85-91
40. Adams W.G., et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. J. Am. Med. Assoc. 269:1993;221-226
41. Zhou F., et al. Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics. 110:2002;653-661
42. Hirota Y., et al. Japan lagging in influenza jabs. Nature. 380:1996;18
43. Reichert T.A., et al. The Japanese experience with vaccinating schoolchildren against influenza. N. Engl. J. Med. 344:2001;889-896
44. Pizza M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 287:2000;1816-1820
45. O'Hagan D.T., Valiante N.M. Recent advances in the discovery and delivery of vaccines and adjuvants. Nat. Rev. Drug Discov. 2:2003;727-735
46. Ott G. The Adjuvant MF59: A 10-year Perspective. O'Hagan D. Vaccine Adjuvants: Preparation Methods and Research Protocols. 2000;211-228 Humana Press
47. Polo J.M., Dubensky T.W. Virus-based vectors for human vaccine applications. Drug Discov. Today. 7:2002;719-727
48. Rappuoli R., et al. Medicine. The intangible value of vaccination. Science. 297:2002;937-939
49. House of Commons (2004) Procurement of vaccines by the Department of Health (HC 429). The House of Commons (http://www.publications.parliament.uk/pa/ cm200304/cmselect/cmpubacc/429/429.pdf)
50. Poland G.A., Jacobson R.M. Understanding those who do not understand: a brief review of the anti-vaccine movement. Vaccine. 19:2001;2440-2445
51. Kapikian A.Z., et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:1969;405-421
52. Minor P.D. Attenuation and reversion of the Sabin vaccine strains of poliovirus. Dev. Biol. Stand. 78:1993;17-26
53. Fulginiti V.A., et al. Altered reactivity to measles virus: local reactions following attenuated measles virus immunization in children who previously received a combination of inactivated and attenuated vaccines. Am. J. Dis. Child. 115:1968;671-676
54. Mutsch M., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 50:2004;896-903
55. Pittman P.R., et al. Anthrax vaccine: short-term safety experience in humans. Vaccine. 20:2001;972-978
56. Langmuir A.D., et al. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am. J. Epidemiol. 119:1984;841-879